Matisse Capital’s Fulcrum Therapeutics FULC Stock Holding History

Matisse Capital’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-39,649	Closed	-$304K	–	167
2026 Q1	$304K	Buy	39,649 +26,189	+195%	+$243K	0.13%	144
2025 Q4	$152K	Sell	13,460 -5,170	-28%	-$52.6K	0.07%	166
2025 Q3	$171K	Sell	18,630 -7,470	-29%	-$54K	0.08%	159
2025 Q2	$180K	Sell	26,100 -70,617	-73%	-$378K	0.08%	164
2025 Q1	$279K	Sell	96,717 -31,728	-25%	-$117K	0.15%	142
2024 Q4	$604K	Buy	128,445 +21,728	+20%	+$80.2K	0.31%	98
2024 Q3	$381K	Buy	+106,717	New	+$792K	0.19%	127

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Matisse Capital's FULC Position: Q2 2026 in Review

Matisse Capital sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 39,649 shares — an estimated $304K sold.

Matisse Capital first reported a position in FULC in Q3 2024 and held it in 7 quarters. The position peaked at $604K in Q4 2024. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Matisse Capital reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
Matisse Capital sold 39,649 Fulcrum Therapeutics shares in Q2 2026, an estimated $304K.
Matisse Capital first reported a position in Fulcrum Therapeutics in Q3 2024 and held it in 7 quarters.
Matisse Capital's Fulcrum Therapeutics position peaked at $604K in Q4 2024.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Matisse Capital's 13F filing for Q2 2026, filed 12 Aug 2026.